### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### **FORM 10-Q**

(Mark One)

**☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the quarterly period ended June 30, 2021

Or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

Commission file number 000-30941

#### **AXCELIS TECHNOLOGIES, INC.**

(Exact name of registrant as specified in its charter)

Delaware

incorporation or organization)

(State or other jurisdiction of

34-1818596

(IRS Employer Identification No.)

108 Cherry Hill Drive Beverly, Massachusetts 01915

(Address of principal executive offices, including zip code)

(978) 787-4000

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which
		registered
Common Stock, \$0.001 par value	ACLS	Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  $\boxtimes$  No  $\square$ .

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  $\boxtimes$  No  $\square$ .

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

nd energing growth company in Nate 125-2 of the Exchange Act.	
Large accelerated filer ⊠	Accelerated filer $\square$
Non-accelerated filer $\square$	Smaller reporting company $\square$
	Emerging growth company $\square$
If an emerging growth company, indicate by check mark if registrant has with any new or revised financial accounting standards provided pursuant to	
Indicate by check mark whether the registrant is a shell company (as define	ned in Rule 12b-2 of the Exchange Act) Yes $\square$ No $\boxtimes$
As of August 3, 2021 there were 33,574,743 shares of the registrant's cor	mmon stock outstanding.

#### **Table of Contents**

PART I - FINANCIAL	INFORMATION
--------------------	-------------

<u>Item 1.</u>	<u>Financial Statements (Unaudited)</u>	
	Consolidated Statements of Operations for the three and six months ended June 30, 2021 and 2020	3
	Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2021 and	
	<u>2020</u>	4
	Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020	5
	Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2021 and 2020	6
	Consolidated Statements of Cash Flows for the six months ended June 30, 2021 and 2020	7
	Notes to Consolidated Financial Statements (Unaudited)	8
<u>Item 2.</u>	Management's Discussion and Analysis of Financial Condition and Results of Operations	19
	<u>Overview</u>	19
	Critical Accounting Estimates	19
	Results of Operations	20
	<u>Liquidity and Capital Resources</u>	26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4.	Controls and Procedures	28
PART II	I - OTHER INFORMATION	29
<u>Item 1.</u>	<u>Legal Proceedings</u>	29
Item 1A	Risk Factors	29
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	29
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	29
Item 4.	Mine Safety Disclosures	29
<u>Item 5.</u>	Other Information	29
Item 6.	Exhibits	30

#### PART 1—FINANCIAL INFORMATION

Item 1. Financial Statements.

## Axcelis Technologies, Inc. Consolidated Statements of Operations (In thousands, except per share amounts) (Unaudited)

		Three months ended June 30,			Six mon Jui	ths er ie 30,	ıded
		2021		2020	2021		2020
Revenue:							
Product	\$	140,156	\$	117,194	\$ 266,765	\$	229,327
Services		7,118		5,771	 13,285		12,629
Total revenue		147,274		122,965	 280,050		241,956
Cost of revenue:							
Product		76,688		65,519	147,022		132,691
Services		6,572		5,547	 12,579		11,817
Total cost of revenue		83,260		71,066	159,601		144,508
Gross profit		64,014		51,899	120,449		97,448
Operating expenses:							
Research and development		16,623		16,040	32,308		30,646
Sales and marketing		12,177		9,437	22,564		17,641
General and administrative		11,217		10,041	21,230		19,077
Total operating expenses	·	40,017		35,518	76,102		67,364
Income from operations		23,997		16,381	 44,347		30,084
Other (expense) income:							
Interest income		40		70	73		552
Interest expense		(1,274)		(1,299)	(2,303)		(2,602)
Other, net		(15)		421	(1,168)		(199)
Total other expense		(1,249)		(808)	(3,398)		(2,249)
Income before income taxes		22,748		15,573	 40,949		27,835
Income tax provision		3,842		2,271	5,563		3,312
Net income	\$	18,906	\$	13,302	\$ 35,386	\$	24,523
Net income per share:							
Basic	\$	0.56	\$	0.40	\$ 1.05	\$	0.74
Diluted	\$	0.55	\$	0.39	\$ 1.03	\$	0.72
Shares used in computing net income per share:	_						
Basic weighted average common shares	_	33,677		33,116	33,696		32,998
Diluted weighted average common shares		34,311		33,958	34,473		34,023
	_						

# Axcelis Technologies, Inc. Consolidated Statements of Comprehensive Income (In thousands) (Unaudited)

		nths ended e 30,		hs ended e 30,
	2021	2020	2021	2020
Net income	\$ 18,906	\$ 13,302	\$ 35,386	\$ 24,523
Other comprehensive income (loss):				
Foreign currency translation adjustments	552	836	(820)	(276)
Amortization of actuarial loss and other adjustments from pension plan,				
net of tax	34	57	54	114
Total other comprehensive income (loss)	586	893	(766)	(162)
Comprehensive income	\$ 19,492	\$ 14,195	\$ 34,620	\$ 24,361

## Axcelis Technologies, Inc. Consolidated Balance Sheets (In thousands, except per share amounts) (Unaudited)

	June 30, 2021		De	cember 31, 2020
ASSETS				
Current assets:				
Cash and cash equivalents	\$	219,731	\$	203,479
Accounts receivable, net		79,544		86,865
Inventories, net		192,321		161,076
Prepaid expenses and other current assets		22,535		19,371
Total current assets		514,131		470,791
Property, plant and equipment, net		30,683		29,840
Operating lease assets		7,626		4,542
Finance lease assets, net		19,889		20,544
Long-term restricted cash		755		753
Deferred income taxes		51,386		57,851
Other assets		36,170		40,303
Total assets	\$	660,640	\$	624,624
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:				
Accounts payable	\$	40,695	\$	24,013
Accrued compensation		14,906		24,562
Warranty		4,690		4,280
Income taxes		622		654
Deferred revenue		34,112		21,221
Current portion of finance lease obligation		864		756
Other current liabilities		10,585		8,945
Total current liabilities		106,474		84,431
Long-term finance lease obligation		46,923		47,393
Long-term deferred revenue		1,406		1,837
Other long-term liabilities		11,735		9,361
Total liabilities		166,538		143,022
Commitments and contingencies (Note 16)				
Stockholders' equity:				
Common stock, \$0.001 par value, 75,000 shares authorized; 33,657 shares issued and				
outstanding at June 30, 2021; 33,633 shares issued and outstanding at December 31, 2020		34		34
Additional paid-in capital		561,680		570,102
Accumulated deficit		(70,281)		(91,969)
Accumulated other comprehensive income		2,669		3,435
Total stockholders' equity		494,102		481,602
Total liabilities and stockholders' equity	\$	660,640	\$	624,624

## Axcelis Technologies, Inc. Consolidated Statements of Stockholders' Equity (In thousands) (Unaudited)

Accumulated

	Commo Shares	n Stoo			dditional Paid-in Capital	Accumulated Deficit		Comp	omulated Other orehensive me (Loss)	Sto	Total ockholders' Equity
Balance at December 31, 2019	32,585	\$	33	\$	559,878	\$ (	(140,226)	\$	(258)	\$	419,427
Net income			_		_		11,221		_		11,221
Foreign currency translation adjustments	_		_		_		_		(1,112)		(1,112)
Change in pension obligation	_		_		_		_		57		57
Exercise of stock options	540		1		4,498		_		_		4,499
Issuance of shares under Employee Stock											,
Purchase Plan	1		_		19		_		_		19
Issuance of restricted common shares,											
net of shares withheld	69		_		(1,162)		_		_		(1,162)
Stock-based compensation expense	_		_		1,724		_		_		1,724
Repurchase of common stock	(358)		(1)		(5,775)		(1,725)		_		(7,501)
Balance at March 31, 2020	32,837	\$	33	\$	559,182	\$ (	(130,730)	\$	(1,313)	\$	427,172
Net income		_	_			_	13,302			_	13,302
Foreign currency translation adjustments	_		_		_		15,502		836		836
Change in pension obligation									57		57
Exercise of stock options	343				2,783				37		2,783
Issuance of shares under Employee Stock	343		_		2,703						2,763
Purchase Plan	21				490						490
Issuance of restricted common shares,	21				490		_		_		490
net of shares withheld	232		_		(2,698)		_		_		(2,698)
Stock-based compensation expense					3,082						3,082
Balance at June 30, 2020	33,433	\$	33	\$	562,839	\$ (	(117,428)	\$	(420)	\$	445,024
	Comm Shares			į	Additional Paid-in Capital	Ac	cumulated Deficit	Con	cumulated Other nprehensive ome (Loss)	S	Total tockholders' Equity
Balance at December 31, 2020			ock lount 34	\$	Paid-in	<b>Ac</b>		Con	Other	\$	
Balance at December 31, 2020 Net income	Shares	Am	ount		Paid-in Capital		Deficit	Con Inc	Other nprehensive ome (Loss)		tockholders' Equity
	Shares	Am	ount		Paid-in Capital		<b>Deficit</b> (91,969)	Con Inc	Other oprehensive ome (Loss) 3,435		tockholders' Equity 481,602
Net income	Shares	Am	ount		Paid-in Capital		<b>Deficit</b> (91,969)	Con Inc	Other nprehensive ome (Loss)  3,435		Equity 481,602 16,480
Net income Foreign currency translation adjustments	Shares	Am	ount		Paid-in Capital		<b>Deficit</b> (91,969)	Con Inc	Other apprehensive ome (Loss) 3,435 — (1,372)		tockholders' Equity 481,602 16,480 (1,372)
Net income Foreign currency translation adjustments Change in pension obligation	Shares 33,633 — — —	Am	ount		Paid-in Capital 570,102		<b>Deficit</b> (91,969)	Con Inc	Other apprehensive ome (Loss) 3,435 — (1,372)		tockholders' Equity 481,602 16,480 (1,372) 20
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options	Shares 33,633 — — —	Am	ount		Paid-in Capital 570,102		<b>Deficit</b> (91,969)	Con Inc	Other apprehensive ome (Loss) 3,435 — (1,372)		tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354)
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares,	Shares 33,633 — — — 268	Am	ount		Paid-in Capital 570,102 ————————————————————————————————————		<b>Deficit</b> (91,969)	Con Inc	Other apprehensive ome (Loss) 3,435 — (1,372)		tockholders' Equity 481,602 16,480 (1,372) 20 2,512
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld	Shares 33,633 — — — 268	Am	ount		Paid-in Capital 570,102 — — — — — — — 2,512		<b>Deficit</b> (91,969)	Con Inc	Other apprehensive ome (Loss) 3,435 — (1,372)		tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354)
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense	Shares 33,633 — — — 268 81 —	Am	ount		Paid-in Capital 570,102 — — — — — — — 2,512 — (2,354) — 2,407		Deficit (91,969) 16,480	Con Inc	Other apprehensive ome (Loss) 3,435 — (1,372)		tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock	Shares 33,633 — — — 268 81 — (303)	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — 2,512 — (2,354) — 2,407 — (5,468)	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income	Shares 33,633 — — — 268 81 — (303)	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — 2,512 — (2,354) — 2,407 — (5,468)	\$	Deficit (91,969) 16,480 — — — — — — — — — — — — — — — — — — —	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660 18,906
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income Foreign currency translation adjustments	Shares 33,633 — — — 268 81 — (303)	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — 2,512 — (2,354) — 2,407 — (5,468)	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20  ————————————————————————————————	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income	Shares 33,633 — — — 268 81 — (303)	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — 2,512 — (2,354) — 2,407 — (5,468)	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20   2,083   552	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660 18,906 552
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options	Shares 33,633	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — — — — — — — — — — —	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20   2,083   2,083   34	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660 18,906 552 34
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income Foreign currency translation adjustments Change in pension obligation	Shares 33,633	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — — — — — — — — — — —	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20   2,083   2,083   34	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660 18,906 552 34
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of shares under Employee Stock	Shares 33,633  268  81 (303) 33,679 72	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — — — — — — — — — — —	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20   2,083   2,083   34	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660 18,906 552 34 563
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of shares under Employee Stock Purchase Plan	Shares 33,633  268  81 (303) 33,679 72	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — — — — — — — — — — —	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20   2,083   2,083   34	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660 18,906 552 34 563
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of shares under Employee Stock Purchase Plan Issuance of restricted common shares,	Shares 33,633	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102 — — — — — — — — — — — — — — — — — — —	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20   2,083   2,083   34	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660 18,906 552 34 563
Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of restricted common shares, net of shares withheld Stock-based compensation expense Repurchase of common stock Balance at March 31, 2021 Net income Foreign currency translation adjustments Change in pension obligation Exercise of stock options Issuance of shares under Employee Stock Purchase Plan Issuance of restricted common shares, net of shares withheld	Shares 33,633	<u>Am</u> \$	34 ————————————————————————————————————	\$	Paid-in Capital 570,102	\$	Deficit (91,969) 16,480 (6,167) (81,656)	Con Inco \$	Other nprehensive ome (Loss)  3,435  (1,372)  20   2,083   2,083   34	\$	tockholders' Equity 481,602 16,480 (1,372) 20 2,512 (2,354) 2,407 (11,635) 487,660 18,906 552 34 563 509 (4,141)

# Axcelis Technologies, Inc. Consolidated Statements of Cash Flows (In thousands) (Unaudited)

Total Income (ash flows from operating activities)           Net income         \$ 35,386         \$ 24,523           Adjustments to reconcile net income to net cash provided by operating activities:         5,336         4,829           Deperciation and amortization         5,336         4,829           Deferred income taxes         5,107         3,035           Stock-based compensation expense         5,784         4,806           Provision for excess and obsolete inventory         1,888         1,708           Changes in operating assets and liabilities:         7,091         18,752           Inventories         (32,418)         (9,123)           Inventories and other current assets         (3,309)         (4,206)           Accounts payable and other current liabilities         7,282         11,808           Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         1,341         (729)           Net cash provided by operating activities         45,921         56,575           Cash flows from investing activities         (2,392)         (2,975)           Net cash used in investing activities         (2,392)         (2,975)           Net settlement on restricted stock grants		Six months ended June 30,				
Net income         \$ 35,386         \$ 24,523           Adjustments to reconcile net income to net cash provided by operating activities:         \$ 5,336         4,829           Depreciation and amortization         5,336         4,829           Deferred income taxes         5,107         3,035           Stock-based compensation expense         5,784         4,806           Provision for excess and obsolete inventory         1,888         1,708           Changes in operating assets and liabilities:         7,091         18,752           Inventories         (32,418)         (9,123)           Inventories         (3,309)         (4,206)           Accounts payable and other current assets         (3,309)         (4,206)           Accounts payable and other current liabilities         7,282         11,808           Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         1,341         (729)           Net cash provided by operating activities         2,392         2,975           Cash flows from investing activities         2,392         2,975           Expenditures for property, plant and equipment and capitalized software         2,392         2,975           Net cash used in inv		2021	2020			
Adjustments to reconcile net income to net cash provided by operating activities:         5,336         4,829           Deperciation and amortization         5,336         4,829           Deferred income taxes         5,107         3,035           Stock-based compensation expense         5,784         4,806           Provision for excess and obsolete inventory         1,888         1,708           Changes in operating assets and liabilities:	Cash flows from operating activities					
Depreciation and amortization         5,336         4,829           Deferred income taxes         5,107         3,035           Stock-based compensation expense         5,784         4,806           Provision for excess and obsolete inventory         1,888         1,708           Changes in operating assets and liabilities:         7,091         18,752           Inventories         (32,418)         (9,123)           Prepaid expenses and other current assets         (3,309)         (4,206)           Accounts payable and other current liabilities         7,282         11,808           Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         1,341         (729)           Net cash provided by operating activities         45,921         56,575           Cash flows from investing activities         2,392         (2,975)           Expenditures for property, plant and equipment and capitalized software         (2,392)         (2,975)           Cash flows from financing activities         (2,392)         (2,975)           Cash flows from financing activities         (6,495)         (3,860)           Repurchase of common stock         (24,993)         (7,501)           Proceeds from E		\$ 35,386	\$ 24,523			
Deferred income taxes         5,107         3,035           Stock-based compensation expense         5,784         4,806           Provision for excess and obsolete inventory         1,888         1,708           Changes in operating assets and liabilities:         7,091         18,752           Inventories         (32,418)         (9,123)           Prepaid expenses and other current assets         (3,309)         (4,206)           Accounts payable and other current liabilities         7,282         11,808           Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         (27)         5           Other assets and liabilities         45,921         56,575           Cash flows from investing activities         (27)         5           Expenditures for property, plant and equipment and capitalized software         (2,392)         (2,975)           Net cash used in investing activities         (2,392)         (2,395)           Cash flows from financing activities         (6,495)         (3,860)           Repurchase of common stock         (24,993)         (7,501)           Proceeds from Employee Stock Purchase Plan         508         509           Principal payments on finance						
Stock-based compensation expense         5,784         4,806           Provision for excess and obsolete inventory         1,888         1,708           Changes in operating assets and liabilities:						
Provision for excess and obsolete inventory         1,888         1,708           Changes in operating assets and liabilities:         7,091         18,752           Accounts receivable         7,091         18,752           Inventories         (32,418)         (9,123)           Prepaid expenses and other current assets         (3,309)         (4,206)           Accounts payable and other current liabilities         7,282         11,808           Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         1,341         (729)           Net cash provided by operating activities         45,921         56,575           Cash flows from investing activities         2         2           Expenditures for property, plant and equipment and capitalized software         (2,392)         (2,975)           Net cash used in investing activities         (2,392)         (2,975)           Cash flows from financing activities         (6,495)         (3,860)           Repurchase of common stock         (24,993)         (7,501)           Proceeds from Employee Stock Purchase Plan         508         509           Principal payments on finance lease obligation         (362)         (108)           Pr			,			
Changes in operating assets and liabilities:         7,091         18,752           Inventories         (32,418)         (9,123)           Prepaid expenses and other current assets         (3,309)         (4,206)           Accounts payable and other current liabilities         7,282         11,808           Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         1,341         (729)           Net cash provided by operating activities         45,921         56,575           Cash flows from investing activities         (2,392)         (2,975)           Net cash used in investing activities         (2,392)         (2,975)           Cash flows from financing activities         (6,495)         (3,860)           Repurchase of common stock         (24,993)         (7,501)           Proceeds from Employee Stock Purchase Plan         508         509           Principal payments on finance lease obligation         (362)         (108)           Proceeds from exercise of stock options         3,075         7,282           Net cash used in financing activities         (28,267)         (3,678)           Effect of exchange rate changes on cash and cash equivalents         992         560		5,784	4,806			
Accounts receivable         7,091         18,752           Inventories         (32,418)         (9,123)           Prepaid expenses and other current assets         (3,309)         (4,206)           Accounts payable and other current liabilities         7,282         11,808           Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         1,341         (729)           Net cash provided by operating activities         45,921         56,575           Cash flows from investing activities         (2,392)         (2,975)           Net cash used in investing activities         (2,392)         (2,975)           Net settlement on restricted stock grants         (6,495)         (3,860)           Repurchase of common stock         (24,993)         (7,501)           Proceeds from Employee Stock Purchase Plan         508         509           Principal payments on finance lease obligation         (362)         (108)           Proceeds from exercise of stock options         3,075         7,282           Net cash used in financing activities         (28,267)         (3,678)           Effect of exchange rate changes on cash and cash equivalents         992         560           Net increas	Provision for excess and obsolete inventory	1,888	1,708			
Inventories   (32,418)   (9,123)     Prepaid expenses and other current assets   (3,309)   (4,206)     Accounts payable and other current liabilities   7,282   11,808     Deferred revenue   12,460   1,167     Income taxes   (27)   5     Other assets and liabilities   1,341   (729)     Net cash provided by operating activities   45,921   56,575      Cash flows from investing activities     Expenditures for property, plant and equipment and capitalized software   (2,392)   (2,975)     Net cash used in investing activities   (2,392)   (2,975)     Cash flows from financing activities   (2,392)   (2,975)     Cash flows from financing activities   (3,860)     Repurchase of common stock   (24,993)   (7,501)     Proceeds from Employee Stock Purchase Plan   508   509     Principal payments on finance lease obligation   (362)   (108)     Proceeds from exercise of stock options   (3,075   7,282     Net cash used in financing activities   (28,267)   (3,678)     Effect of exchange rate changes on cash and cash equivalents   992   560     Net increase in cash, cash equivalents and restricted cash at beginning of period   204,232   146,534	Changes in operating assets and liabilities:					
Prepaid expenses and other current lassets         (3,309)         (4,206)           Accounts payable and other current liabilities         7,282         11,808           Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         1,341         (729)           Net cash provided by operating activities         45,921         56,575           Cash flows from investing activities         (2,392)         (2,975)           Net cash used in investing activities         (2,392)         (2,975)           Net settlement on restricted stock grants         (6,495)         (3,860)           Repurchase of common stock         (24,993)         (7,501)           Proceeds from Employee Stock Purchase Plan         508         509           Principal payments on finance lease obligation         (362)         (108)           Proceeds from exercise of stock options         3,075         7,282           Net cash used in financing activities         (28,267)         (3,678)           Effect of exchange rate changes on cash and cash equivalents         992         560           Net increase in cash, cash equivalents and restricted cash         16,254         50,482	Accounts receivable	7,091	18,752			
Accounts payable and other current liabilities 7,282 11,808 Deferred revenue 12,460 1,167 Income taxes (27) 5 Other assets and liabilities 1,341 (729) Net cash provided by operating activities 45,575  Cash flows from investing activities  Expenditures for property, plant and equipment and capitalized software (2,392) (2,975) Net cash used in investing activities (2,392) (2,975) Net settlement on restricted stock grants Net settlement on restricted stock grants (6,495) (3,860) Repurchase of common stock (24,993) (7,501) Proceeds from Employee Stock Purchase Plan 508 509 Principal payments on finance lease obligation (362) (108) Proceeds from exercise of stock options 3,075 7,282 Net cash used in financing activities (28,267) (3,678)  Effect of exchange rate changes on cash and cash equivalents 992 560 Net increase in cash, cash equivalents and restricted cash at beginning of period 204,232 146,534	Inventories	(32,418)	(9,123)			
Deferred revenue         12,460         1,167           Income taxes         (27)         5           Other assets and liabilities         1,341         (729)           Net cash provided by operating activities         45,921         56,575           Cash flows from investing activities           Expenditures for property, plant and equipment and capitalized software         (2,392)         (2,975)           Net cash used in investing activities         (2,392)         (2,975)           Cash flows from financing activities           Net settlement on restricted stock grants         (6,495)         (3,860)           Repurchase of common stock         (24,993)         (7,501)           Proceeds from Employee Stock Purchase Plan         508         509           Principal payments on finance lease obligation         (362)         (108)           Proceeds from exercise of stock options         3,075         7,282           Net cash used in financing activities         (28,267)         (3,678)           Effect of exchange rate changes on cash and cash equivalents         992         560           Net increase in cash, cash equivalents and restricted cash at beginning of period         204,232         146,534	Prepaid expenses and other current assets	(3,309)	(4,206)			
Income taxes (27) 5 Other assets and liabilities 1,341 (729) Net cash provided by operating activities 45,921 56,575  Cash flows from investing activities  Expenditures for property, plant and equipment and capitalized software (2,392) (2,975) Net cash used in investing activities (2,392) (2,975)  Net settlement on restricted stock grants (6,495) (3,860) Repurchase of common stock (24,993) (7,501) Proceeds from Employee Stock Purchase Plan 508 509 Principal payments on finance lease obligation (362) (108) Proceeds from exercise of stock options 3,075 7,282 Net cash used in financing activities (28,267) (3,678)  Effect of exchange rate changes on cash and cash equivalents 992 560 Net increase in cash, cash equivalents and restricted cash at beginning of period 204,232 146,534	Accounts payable and other current liabilities	7,282	11,808			
Other assets and liabilities1,341 45,921(729)Net cash provided by operating activities45,92156,575Cash flows from investing activitiesExpenditures for property, plant and equipment and capitalized software(2,392)(2,975)Net cash used in investing activities(2,392)(2,975)Cash flows from financing activitiesNet settlement on restricted stock grants(6,495)(3,860)Repurchase of common stock(24,993)(7,501)Proceeds from Employee Stock Purchase Plan508509Principal payments on finance lease obligation(362)(108)Proceeds from exercise of stock options3,0757,282Net cash used in financing activities(28,267)(3,678)Effect of exchange rate changes on cash and cash equivalents992560Net increase in cash, cash equivalents and restricted cash16,25450,482Cash, cash equivalents and restricted cash at beginning of period204,232146,534	Deferred revenue	12,460	1,167			
Net cash provided by operating activities  Cash flows from investing activities  Expenditures for property, plant and equipment and capitalized software (2,392) (2,975)  Net cash used in investing activities (2,392) (2,975)  Cash flows from financing activities  Net settlement on restricted stock grants  Net settlement on restricted stock grants (6,495) (3,860)  Repurchase of common stock (24,993) (7,501)  Proceeds from Employee Stock Purchase Plan 508 509  Principal payments on finance lease obligation (362) (108)  Proceeds from exercise of stock options 3,075 7,282  Net cash used in financing activities (28,267) (3,678)  Effect of exchange rate changes on cash and cash equivalents 992 560  Net increase in cash, cash equivalents and restricted cash 16,254 50,482	Income taxes	(27)	5			
Cash flows from investing activities  Expenditures for property, plant and equipment and capitalized software  (2,392) (2,975)  Net cash used in investing activities  (2,392) (2,975)  Cash flows from financing activities  Net settlement on restricted stock grants  Repurchase of common stock (24,993) (7,501)  Proceeds from Employee Stock Purchase Plan Principal payments on finance lease obligation Proceeds from exercise of stock options Another than 2,005  Net cash used in financing activities  Effect of exchange rate changes on cash and cash equivalents  Net increase in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash at beginning of period  204,232 146,534	Other assets and liabilities	1,341	(729)			
Expenditures for property, plant and equipment and capitalized software Net cash used in investing activities  Cash flows from financing activities  Net settlement on restricted stock grants Repurchase of common stock Proceeds from Employee Stock Purchase Plan Principal payments on finance lease obligation Proceeds from exercise of stock options Net cash used in financing activities  Effect of exchange rate changes on cash and cash equivalents Net increase in cash, cash equivalents and restricted cash at beginning of period  (2,392) (2,975)  (2,975)  (2,975)  (2,975)  (3,860) (6,495) (3,860) (24,993) (7,501	Net cash provided by operating activities	45,921	56,575			
Expenditures for property, plant and equipment and capitalized software Net cash used in investing activities  Cash flows from financing activities  Net settlement on restricted stock grants Repurchase of common stock Proceeds from Employee Stock Purchase Plan Principal payments on finance lease obligation Proceeds from exercise of stock options Net cash used in financing activities  Effect of exchange rate changes on cash and cash equivalents Net increase in cash, cash equivalents and restricted cash at beginning of period  (2,392) (2,975)  (2,975)  (2,975)  (2,975)  (3,860) (6,495) (3,860) (24,993) (7,501						
Net cash used in investing activities (2,392) (2,975)  Cash flows from financing activities  Net settlement on restricted stock grants (6,495) (3,860)  Repurchase of common stock (24,993) (7,501)  Proceeds from Employee Stock Purchase Plan 508 509  Principal payments on finance lease obligation (362) (108)  Proceeds from exercise of stock options 3,075 7,282  Net cash used in financing activities (28,267) (3,678)  Effect of exchange rate changes on cash and cash equivalents 992 560  Net increase in cash, cash equivalents and restricted cash at beginning of period 204,232 146,534	Cash flows from investing activities					
Cash flows from financing activitiesNet settlement on restricted stock grants(6,495)(3,860)Repurchase of common stock(24,993)(7,501)Proceeds from Employee Stock Purchase Plan508509Principal payments on finance lease obligation(362)(108)Proceeds from exercise of stock options3,0757,282Net cash used in financing activities(28,267)(3,678)Effect of exchange rate changes on cash and cash equivalents992560Net increase in cash, cash equivalents and restricted cash16,25450,482Cash, cash equivalents and restricted cash at beginning of period204,232146,534	Expenditures for property, plant and equipment and capitalized software	(2,392)	(2,975)			
Net settlement on restricted stock grants(6,495)(3,860)Repurchase of common stock(24,993)(7,501)Proceeds from Employee Stock Purchase Plan508509Principal payments on finance lease obligation(362)(108)Proceeds from exercise of stock options3,0757,282Net cash used in financing activities(28,267)(3,678)Effect of exchange rate changes on cash and cash equivalents992560Net increase in cash, cash equivalents and restricted cash16,25450,482Cash, cash equivalents and restricted cash at beginning of period204,232146,534	Net cash used in investing activities	(2,392)	(2,975)			
Net settlement on restricted stock grants(6,495)(3,860)Repurchase of common stock(24,993)(7,501)Proceeds from Employee Stock Purchase Plan508509Principal payments on finance lease obligation(362)(108)Proceeds from exercise of stock options3,0757,282Net cash used in financing activities(28,267)(3,678)Effect of exchange rate changes on cash and cash equivalents992560Net increase in cash, cash equivalents and restricted cash16,25450,482Cash, cash equivalents and restricted cash at beginning of period204,232146,534						
Repurchase of common stock(24,993)(7,501)Proceeds from Employee Stock Purchase Plan508509Principal payments on finance lease obligation(362)(108)Proceeds from exercise of stock options3,0757,282Net cash used in financing activities(28,267)(3,678)Effect of exchange rate changes on cash and cash equivalents992560Net increase in cash, cash equivalents and restricted cash16,25450,482Cash, cash equivalents and restricted cash at beginning of period204,232146,534	Cash flows from financing activities					
Proceeds from Employee Stock Purchase Plan  Principal payments on finance lease obligation  Proceeds from exercise of stock options  Net cash used in financing activities  Effect of exchange rate changes on cash and cash equivalents  Net increase in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash at beginning of period  508  509  (108)  (28,267)  (3,678)  500  Net increase in cash, cash equivalents and restricted cash  16,254  50,482	Net settlement on restricted stock grants	(6,495)	(3,860)			
Proceeds from Employee Stock Purchase Plan Principal payments on finance lease obligation (362) (108) Proceeds from exercise of stock options Net cash used in financing activities (28,267) (3,678)  Effect of exchange rate changes on cash and cash equivalents Net increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period 204,232 146,534	Repurchase of common stock	(24,993)	(7,501)			
Proceeds from exercise of stock options 3,075 7,282 Net cash used in financing activities (28,267) (3,678)  Effect of exchange rate changes on cash and cash equivalents 992 560 Net increase in cash, cash equivalents and restricted cash 16,254 50,482  Cash, cash equivalents and restricted cash at beginning of period 204,232 146,534	Proceeds from Employee Stock Purchase Plan	508	509			
Proceeds from exercise of stock options 3,075 7,282 Net cash used in financing activities (28,267) (3,678)  Effect of exchange rate changes on cash and cash equivalents 992 560 Net increase in cash, cash equivalents and restricted cash 16,254 50,482  Cash, cash equivalents and restricted cash at beginning of period 204,232 146,534	Principal payments on finance lease obligation	(362)	(108)			
Effect of exchange rate changes on cash and cash equivalents  Net increase in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash at beginning of period  204,232  146,534	Proceeds from exercise of stock options	3,075	7,282			
Effect of exchange rate changes on cash and cash equivalents  Net increase in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash at beginning of period  204,232  146,534	Net cash used in financing activities	(28,267)	(3,678)			
Net increase in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash at beginning of period  204,232  146,534		( , ,	( , ,			
Net increase in cash, cash equivalents and restricted cash  Cash, cash equivalents and restricted cash at beginning of period  204,232  146,534	Effect of exchange rate changes on cash and cash equivalents	992	560			
Cash, cash equivalents and restricted cash at beginning of period 204,232 146,534	· · · · · · · · · · · · · · · · · · ·	16,254	50,482			
	, · · · · · · · · · · · · · · · · ·	-,,-	, -			
	Cash, cash equivalents and restricted cash at beginning of period	204,232	146,534			
	,					

### Axcelis Technologies, Inc. Notes to Consolidated Financial Statements (Unaudited)

#### **Note 1. Nature of Business**

Axcelis Technologies, Inc. ("Axcelis" or the "Company") was incorporated in Delaware in 1995 and is a producer of ion implantation equipment used in the fabrication of semiconductor chips in the United States, Europe and Asia. In addition, we provide extensive worldwide aftermarket service and support, including spare parts, equipment upgrades, used equipment and maintenance services to the semiconductor industry.

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments which are of a normal recurring nature and considered necessary for a fair presentation of these financial statements have been included. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for other interim periods or for the year as a whole.

The balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. For further information, refer to the consolidated financial statements and footnotes thereto included in Axcelis Technologies, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2020.

#### Note 2. Stock-Based Compensation

We maintain the Axcelis Technologies, Inc. 2012 Equity Incentive Plan, as amended (the "2012 Equity Plan"), which became effective on May 2, 2012, and permits the issuance of options, restricted stock, restricted stock units ("RSUs") and performance awards to selected employees, directors and consultants of the Company. Our 2000 Stock Plan (the "2000 Stock Plan") expired on May 1, 2012 and no new grants may be made under that plan after that date. However, unexpired options granted under the 2000 Stock Plan, which have a 10-year term, remain outstanding and subject to the terms of the 2000 Stock Plan. We also maintain the Axcelis Technologies, Inc. 2020 Employee Stock Purchase Plan (the "2020 ESPP"), an Internal Revenue Code Section 423 plan. The Company's Employee Stock Purchase Plan, which was effective in June 2000 (the "2000 ESPP"), expired in June 2020.

The 2012 Equity Plan is more fully described in Note 13 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020.

We recognized stock-based compensation expense of \$3.4 million and \$3.1 million for the three-month periods ended June 30, 2021 and 2020, respectively. We recognized stock-based compensation expense of \$5.8 million and \$4.8 million for the six-month periods ended June 30, 2021 and 2020, respectively. These amounts include compensation expense related to RSUs, non-qualified stock options and stock to be issued to participants under the 2020 ESPP and 2000 ESPP.

In the three-month periods ended June 30, 2021 and 2020, we issued 0.3 million and 0.6 million shares of common stock, respectively, upon stock option exercises, purchases under the employee stock purchase plans and vesting of RSUs. In the three-month periods ended June 30, 2021 and 2020, we received proceeds of \$1.1 million and \$3.3 million, respectively, in connection with the exercise of stock options and purchases under the employee stock purchase plans.

In the six-month periods ended June 30, 2021 and 2020, we issued 0.7 million and 1.2 million shares of common stock, respectively, upon stock option exercises, purchases under the employee stock purchase plans and vesting of RSUs. In the six-month periods ended June 30, 2021 and 2020, we received proceeds of \$3.6 million and \$7.8 million, respectively, in connection with the exercise of stock options and purchases under the employee stock purchase plans.

#### Note 3. Leases

We have operating leases for office space, warehouse space, computer and office equipment and vehicles used in our business operations. We have a finance lease as a result of the 2015 sale-leaseback of our corporate headquarters in Beverly, Massachusetts. All new agreements are reviewed to determine if they contain a lease component. A lease is a contract or part of a contract that conveys the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration. We recognize the lease obligation on a discounted basis using the explicit or implicit discount rate stated within the agreement. We recognize a corresponding right-of-use asset, which is initially determined based upon the net present value of the associated liability and is adjusted for deferred costs and possible impairment, if any. For those lease agreements that do not indicate the applicable discount rate, we use our incremental borrowing rate. We have made the following policy elections: (i) operating leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet; (ii) we recognize lease expense for operating leases on a straight-line basis over the lease term; and (iii) we account for lease components and non-lease components that are fixed payments as one component. Some of our operating leases include one or more options to renew, with renewal terms that can extend the respective lease term 1 to 3 years. The exercise of lease renewal options are at our sole discretion. For lease extensions that are reasonably certain to occur, we have included these renewal periods in our calculation of the net present value of the lease obligation and related right-of-use asset. Certain leases also include options to purchase the leased property. The depreciable life of certain assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. The amounts of operating and finance lease right-of-use assets and related lease obligations recorded within our consolidated balance sheets are as follows:

		J	une 30,	Dece	ember 31,
Leases	Classification	2021			2020
Assets	·		(in thou	sands)	
Operating leases	Operating lease assets	\$	7,626	\$	4,542
Finance lease	Finance lease assets *		19,889		20,544
Total leased assets		\$	27,515	\$	25,086
Liabilities			,		
Current					
Operating	Other current liabilities	\$	3,215	\$	2,573
	Current portion of finance lease				
Finance	obligation		864		756
Noncurrent					
Operating	Other long-term liabilities		4,398		1,949
Finance	Finance lease obligation		46,923		47,393
Total lease liabilities		\$	55,400	\$	52,671

<sup>\*</sup> Finance lease assets are recorded net of accumulated depreciation of \$48.9 million and include \$0.7 million of prepaid financing costs as of June 30, 2021. Finance lease assets are recorded net of accumulated depreciation of \$48.4 million and include \$0.7 million of prepaid financing costs as of December 31, 2020.

All of our operating lease office locations support selling and servicing functions. Operating lease expense, and depreciation and interest expense relating to our finance lease obligation, are recognized within our consolidated statement of operations for the three and six months ended June 30, 2021 and 2020 as follows:

	T	hree mon	ths e	Six months ended									
			June 30,				June 30,						
Lease cost	Classification		2021		2021		2021 2020		2020	2020 2021		_	2020
Operating lease cost					(in thous	usands)							
Service	Cost of revenue	\$	644	\$	624	\$	1,283	\$	1,174				
Research and development	Operating expenses		122		128		252		209				
Sales and marketing*	Operating expenses		376		346		755		678				
General and administrative*	Operating expenses		201		220		461		435				
Total operating lease cost		\$	1,343	\$	1,318	\$	2,751	\$	2,496				
Finance lease cost						_		_					
Depreciation of leased assets	Cost of revenue, R&D, Sales and marketing and G&A	\$	328	\$	328	\$	656	\$	681				
Interest on lease liabilities	Interest expense		1,274		1,299		2,553		2,602				
Total finance lease cost	•	\$	1,602	\$	1,627	\$	3,209	\$	3,283				
						_		_					
Total lease cost		\$	2,945	\$	2,945	\$	5,960	\$	5,779				

<sup>\*</sup> Sales and marketing and general and administrative expense also includes short-term lease and variable lease costs of approximately \$0.4 million and \$0.9 million for the three and six months ended June 30, 2021, respectively, and includes short-term and variable lease costs of approximately \$0.3 million and \$0.5 million for the three and six months ended June 30, 2020, respectively.

The lease of our corporate headquarters, shown below under finance leases, had an original lease term of 22 years, beginning in January 2015. All other locations are treated as operating leases, with lease terms ranging from 1 to 10 years. The tables below reflect the minimum cash outflow regarding our current lease obligations as well as the weighted-average remaining lease term and weighted-average discount rates used in our calculation of our lease obligations and right-of-use assets as of June 30, 2021:

Maturity of Lease Liabilities	Finance Leases	i	perating <u>Leases</u> housands)	Total Leases		
2021	\$ 2,929	\$	1,827	\$	4,756	
2022	5,980		3,053		9,033	
2023	6,114		1,544		7,658	
2024	6,252		794		7,046	
2025	5,930		712		6,642	
Thereafter	73,723		545		74,268	
Total lease payments	\$ 100,928	\$	8,475	\$	109,403	
Less interest portion*	 (53,141)		(862)		(54,003)	
Finance lease and operating lease obligations	\$ 47,787	\$	7,613	\$	55,400	

<sup>\*</sup> Finance lease interest calculated using the implied interest rate; operating lease interest calculated using estimated corporate borrowing rate.

Lease term and discount rate	June 30, 2021
Weighted-average remaining lease term (years):	
Operating leases	3.0
Finance leases	15.6
Weighted-average discount rate:	
Operating leases	4.5%
Finance leases	10.5%

Our cash outflows from our operating leases include rent expense and other charges associated with these leases. These cash flows are included within the operating activities section of our statement of cash flows. Our cash flows from our finance lease include both an interest component and payment of principal component. The table below shows our cash outflows, by lease type and related section of our statement of cash flows, as well as the non-cash amount capitalized on our balance sheet in relation to our operating lease right-of-use assets for the six months ending June 30, 2021 and 2020, respectively:

		Six months ended							
		June 30,							
Cash paid for amounts included in the measurement of lease liabilities		2021		2020					
		(in tho	usands)						
Operating cash outflows from operating leases	\$	2,751	\$	2,496					
Operating cash outflows from finance leases		2,556		2,746					
Financing cash outflows from finance leases		362		108					
Operating lease assets obtained in exchange for operating lease liabilities		4,192		1,038					
Finance lease assets obtained in exchange for new finance lease liabilities	\$	_	\$	_					

#### Note 4. Revenue

To reflect the organization of our business operations, we divide revenue into two categories: revenue from sales of new systems and revenue arising from the sale of used systems, parts and labor to customers who own systems, which we refer to as "Aftermarket."

Revenue by categories used by management are as follows:

	Three mo				Six month		led
	Jun	e 30			June	30,	
	 2021		2020		2021		2020
			(in t	thous	sands)		
Systems	\$ 100,138	\$	76,815	\$	181,129	\$	159,152
Aftermarket	47,136		46,150		98,921		82,804
Total Revenue	\$ 147,274	\$	122,965	\$	280,050	\$	241,956

We also consider revenue by geography. Revenue is allocated to geographic markets based upon the location to which our products are shipped and in which our services are performed. Revenue in our principal geographic markets is as follows:

	 Three mo Jun	nths o	ended	Six months ended June 30,			
	 2021		2020		2021		2020
			(in tho	usan	ds)		
North America	\$ 10,204	\$	8,915	\$	19,712	\$	19,576
Asia Pacific	116,642		106,604		220,033		203,432
Europe	20,428		7,446		40,305		18,948
Total Revenue	\$ 147,274	\$	122,965	\$	280,050	\$	241,956

Our system sales revenue transactions give rise to contract liabilities (in the case of pre-payments and the fair value of goods and services to be delivered after the system delivery, such as installation and certain warranty obligations).

Contract liabilities are as follows:

	June 30,	December 31,
	2021	2020
	(in tho	usands)
Contract liabilities	\$ 35,518	\$ 23,058

Contract liabilities are reflected as deferred revenue on the consolidated balance sheet and relate to payments invoiced or received in advance of completion of performance obligations under a contract. Contract liabilities are recognized as revenue upon the fulfillment of performance obligations.

	Three months ended Six months ended	
	June 30, June 30,	
	2021 2020 2021 2020	
	(in thousands)	
Balance, beginning of the period	\$ 22,142 \$ 34,106 \$ 23,058 \$ 29,25	51
Deferral of revenue	21,893 6,248 30,117 10,72	24
Recognition of deferred revenue	(8,517) (9,937) (17,657) (9,55	58)
Balance, end of the period	\$ 35,518 \$ 30,417 \$ 35,518 \$ 30,41	17

The majority of our system transactions have payment terms of 90% due upon shipment of the tool and 10% due upon acceptance. Aftermarket transaction payment terms usually provide that payment is due either within 30 or 60 days after the service is provided or parts delivered.

#### Note 5. Receivables and Allowances for Credit Losses

All trade receivables are reported on the Consolidated Balance Sheets at their amortized cost adjusted for any write-offs and net of allowances for credit losses.

Axcelis maintains an allowance for credit losses, which represent an estimate of expected losses over the remaining contractual life of our receivables, considering current market conditions and estimates for supportable forecasts when appropriate. The estimate is a result of the Company's ongoing assessments and evaluations of collectability, historical loss experience, and future expectations in estimating credit losses in our receivable portfolio. Axcelis uses historical loss experience rates and applies them to a related aging analysis while also considering customer and/or economic risk where appropriate. Determination of the proper amount of allowances requires management to exercise judgment about the timing, frequency and severity of credit losses that could materially affect the provision for credit losses and, as a result, net earnings. The allowance takes into consideration numerous quantitative and qualitative factors that include receivable type, historical loss experience, loss migration, delinquency trends, collection experience, current economic conditions, estimates for supportable forecasts, when appropriate, and credit risk characteristics.

Axcelis evaluates the credit risk of the customer when extending credit based on a combination of various financial and qualitative factors that may affect our customers' ability to pay. These factors may include the customer's financial condition, past payment experience, and credit bureau report, as well as the value of the underlying collateral.

Management performs detailed reviews of Axcelis' receivables on a quarterly basis to assess the adequacy of the allowances and to determine if any impairment has occurred. Amounts determined to be uncollectable are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances. Changes to the allowances for credit losses are maintained through adjustments to the provision for credit losses, which are charged to current period earnings.

The following table shows changes of the allowances for credit losses related to trade receivables for the three and six months ended June 30, 2021 and 2020, respectively:

	T		nths ended e 30,		Six months ende		
	2	2021	2020		2021	2020	
			(in	thousan	ds)		
Balance, beginning of period	\$	_	\$ -	- \$	_ \$	818	
Provision for credit losses		_	-	_	_	_	
Charge-offs		_	-	_	_	(818)	
Recoveries		_	-	_	_	_	
Balance, end of period	\$	_	\$ -	- \$	<u> </u>	_	

#### Note 6. Computation of Net Earnings per Share

Basic earnings per share is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased by the number of additional common shares that would have been outstanding if the potentially dilutive common shares issuable on exercise of stock options and vesting of RSUs had been issued, calculated using the treasury stock method.

The components of net earnings per share are as follows:

	Three mor Jun	iths ended e 30,		ths ended e 30,
	2021	2020	2021	2020
	(in tho	usands, excep	t per share ar	nounts)
Net income available to common stockholders	\$ 18,906	\$ 13,302	\$ 35,386	\$ 24,523
Weighted average common shares outstanding used in computing basic income per				
share	33,677	33,116	33,696	32,998
Incremental options and RSUs	634	842	777	1,025
Weighted average common shares used in computing diluted net income per share	34,311	33,958	34,473	34,023
Net income per share				
Basic	\$ 0.56	\$ 0.40	\$ 1.05	\$ 0.74
Diluted	\$ 0.55	\$ 0.39	\$ 1.03	\$ 0.72

Diluted weighted average common shares outstanding does not include 1,800 and 3,138 common equivalent shares issuable with respect to outstanding equity awards for the three-month periods ended June 30, 2021 and 2020, respectively, or 1,352 and 5,006 common equivalent shares issuable with respect to outstanding equity awards for the six-month periods ending June 30, 2021 and 2020, respectively, as their effect would have been anti-dilutive.

#### Note 7. Accumulated Other Comprehensive Income

The following table presents the changes in accumulated other comprehensive income, net of tax, by component, for the six months ended June 30, 2021:

	Foreign currency	per	ned benefit nsion plan in thousands	 Total
Balance at December 31, 2020	\$ 3,945	\$	(510)	\$ 3,435
Other comprehensive loss and pension reclassification	(820)		54	(766)
Balance at June 30, 2021	\$ 3,125	\$	(456)	\$ 2,669

#### Note 8. Cash, cash equivalents and restricted cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets to the total of the amounts shown in the statement of cash flows:

	June 30, 2021	Ι	December 31, 2020
	 (in tho	usands)	
Cash and cash equivalents	\$ 219,731	\$	203,479
Long-term restricted cash	755		753
Total cash, cash equivalents and restricted cash	\$ 220,486	\$	204,232

As of June 30, 2021, we had \$0.8 million in restricted cash representing the total of (i) cash collateral for a \$0.7 million letter of credit relating to workers' compensation insurance and (ii) a \$0.1 million deposit relating to customs activity.

#### Note 9. Inventories, net

The components of inventories are as follows:

	ie 30, 021	December 31, 2020
	(in thous	ands)
Raw materials	\$ 109,795	\$ 100,254
Work in process	40,233	33,867
Finished goods (completed systems)	42,293	26,955
Inventories, net	\$ 192,321	\$ 161,076

When recorded, inventory reserves reduce the carrying value of inventories to their net realizable value. We establish inventory reserves when conditions exist that indicate inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for the Company's products or market conditions. We regularly evaluate the ability to realize the value of inventories based on a combination of factors including the following: forecasted sales or usage, estimated product end of life dates, estimated current and future market value and new product introductions. Purchasing and usage alternatives are also explored to mitigate inventory exposure.

#### Note 10. Product Warranty

We generally offer a one-year warranty for all of our systems, the terms and conditions of which vary depending upon the product sold. For all systems sold, we accrue a liability for the estimated cost of standard warranty at the time of system shipment and defer the portion of systems revenue attributable to the fair value of non-standard warranty. Costs for non-standard warranty are expensed as incurred. Factors that affect our warranty liability include the number of installed units, historical and anticipated product failure rates, material usage and service labor costs. We periodically assess the adequacy of our recorded liability and adjust the amount as necessary.

The changes in our standard product warranty liability are as follows:

		ths ended e 30,
	2021 (in tho	2020 usands)
Balance at January 1 (beginning of year)	\$ 4,612	\$ 3,244
Warranties issued during the period	3,013	2,635
Settlements made during the period	(1,991)	(1,913)
Changes in estimate of liability for pre-existing warranties during the period	(372)	177
Balance at June 30 (end of period)	\$ 5,262	\$ 4,143
Amount classified as current	\$ 4,690	\$ 3,942
Amount classified as long-term	572	201
Total warranty liability	\$ 5,262	\$ 4,143

#### Note 11. Fair Value Measurements

Certain assets on our balance sheets are reported at their fair value. Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

#### (a) Fair Value Hierarchy

The accounting guidance for fair value measurement requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is as follows:

<u>Level 1</u> - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

<u>Level 2</u> - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

<u>Level 3</u> - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

#### (b) Fair Value Measurements

Our money market funds and short-term investments are included in cash and cash equivalents in the consolidated balance sheets.

The following table sets forth our assets by level within the fair value hierarchy:

			June 30, 'alue Me		ents			
	Level 1 Level 2 Level 3 Total							
		- (	(in thous	ands)				
Assets								
Cash equivalents:								
Money market funds, U.S. Government Securities and Agency								
Investments	\$ 190,731	\$	_	\$	—	\$ 190,731		
			cember (					
	Level 1	Leve	el 2 (in thous		vel 3	Total		
Assets				ĺ				
Cash equivalents:								
Money market funds, U.S. Government Securities and Agency	Ф. 4 <b>5</b> 0.440	ф		4		ф. 4 <b>5</b> 0.440		
Investments	\$ 172,119	\$		\$	—	\$ 172,119		

#### (c) Other Financial Instruments

The carrying amounts reflected in the consolidated balance sheets for accounts receivable, prepaid expenses and other current assets and non-current assets, restricted cash, accounts payable and accrued expenses approximate fair value due to their short-term maturities.

#### **Note 12. Financing Arrangements**

On January 30, 2015, we sold our corporate headquarters facility in Beverly, Massachusetts for \$48.9 million. As part of the sale, we also entered into a 22-year lease agreement of our headquarters facility. This sale-leaseback is accounted for as a financing lease under generally accepted accounting principles and, as such, we have recorded a financing obligation of \$47.8 million as of June 30, 2021. The associated lease payments include both an interest component and payment of principal, with the remaining liability being extinguished at the end of the original lease term. We posted a security deposit of \$5.9 million in the form of an irrevocable letter of credit at the time of the closing. This letter of credit reduces our availability under our credit facility, as described in the next paragraph.

On July 31, 2020, we entered into a Senior Secured Credit Facilities Credit Agreement (the "Credit Agreement") with Silicon Valley Bank, in its capacity as administrative agent and collateral agent for itself and as a lender, and such other banks and financial institutions or entities that from time to time join as lenders under the Credit Agreement. The Credit Agreement provides for a revolving credit facility in an aggregate principal amount not to exceed \$40.0 million. Our obligations under the Credit Agreement are secured by a security interest, senior to any current and future debts and to any security interest, in all of our rights, title, and interest in, to and under substantially all of our assets, subject to limited exceptions, including permitted liens. The revolving credit facility terminates on July 31, 2023. As of June 30, 2021, we were in compliance with all covenant requirements of the Credit Agreement. As of such date, no borrowings had been made under the Credit Agreement, although a letter of credit for \$5.9 million reduces the funds available for borrowing under the credit line. We entered into a First Amendment to the Credit Agreement with Silicon Valley Bank in March 2021 to (i) align the covenants with our 2021 stock repurchase program, and (ii) established terms to transition from a Eurodollar based interest rate option to an interest rate benchmark using a secured overnight financing rate (known as "SOFR") published by the Federal Reserve Bank of New York.

#### Note 13. Income Taxes

Income tax expense was \$3.8 million for the three months ended June 30, 2021, compared to \$2.3 million for the three months ended June 30, 2020. The \$1.5 million increase was primarily due to a \$7.2 million increase in pretax income. Income tax expense was \$5.6 million during the six months ended June 30, 2021, compared with \$3.3 million for the six months ended June 30, 2020. The \$2.3 million increase was primarily due to a \$13.1 million increase in pretax income.

The effective tax rate for the three and six months ended June 30, 2021 and 2020, respectively, was less than the U.S. statutory rate of 21% due to favorable discrete items related to equity compensation in those periods and Federal research and development tax credits that reduce the annual tax rate.

We had \$51.4 million and \$57.9 million of net deferred tax assets worldwide relating to net operating loss carryforwards, tax credit carryforwards and other temporary differences, as of June 30, 2021 and December 31, 2020, respectively. These deferred tax assets are available to reduce income taxes in future years. We have a \$9.1 million valuation allowance in the U.S. against certain tax credits and state net operating losses due to the uncertainty of their realization based on long-term Company forecasts and the expiration dates on these tax assets. If future operating results of the Company within the U.S. or these foreign jurisdictions are significantly less than our expectations, it is reasonably possible that we would be required to record an additional valuation allowance on our deferred tax assets in the future.

#### Note 14. Concentration of Risk

For the three months ended June 30, 2021, two customers accounted for 19.7% and 10.2% of total revenue, respectively. For the three months ended June 30, 2020, three customers accounted for 22.5%, 22.2% and 11.6% of total revenue, respectively.

For the six months ended June 30, 2021, one customer accounted for 24.4% of total revenue. For the six months ended June 30, 2020, three customers accounted for 19.7%, 18.5% and 16.2% of total revenue, respectively.

At June 30, 2021, two customers accounted for 11.7% and 10.0% of accounts receivable, respectively. At December 31, 2020, two customers accounted for 23.8% and 11.9% of accounts receivable, respectively.

#### **Note 15. Share Repurchase**

In December 2020, our Board of Directors approved stock repurchases of up to \$100 million of our common stock through the end of 2021. During the six months ended June 30, 2021, we purchased 0.6 million shares at an average cost of \$39.92 per share. The timing and actual number of shares repurchased under this program will depend on various factors including price, corporate and regulatory requirements, alternative investment opportunities and other market conditions.

Shares repurchased by us are accounted for when the transaction is settled. Shares repurchased and retired are deducted from common stock for par value and from additional paid-in capital for the excess over par value. If additional paid-in capital has been exhausted, the excess over par value is deducted from retained earnings. Direct costs incurred to acquire the shares are included in the total cost of the shares.

#### Note 16. Contingencies

#### (a) Litigation

We are from time to time a party to litigation that arises in the normal course of our business operations. We are not presently a party to any litigation that we believe might have a material adverse effect on our business operations.

#### (b) Indemnifications

Our system sales agreements typically include provisions under which we agree to take certain actions, provide certain remedies and defend our customers against third-party claims of intellectual property infringement under specified conditions and indemnify customers against any damage and costs awarded in connection with such claims. We have not incurred any material costs as a result of such indemnifications and have not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.

#### Note 17. Recent Accounting Guidance

#### i. Accounting Standards Update 2019-12 Income Taxes (Topic 740)

We adopted Financial Accounting Standards Board ASU No. 2019-12 "*Income Taxes (Topic 740)*" as of January 1, 2021 on a prospective basis. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions from the previous standard as well as requiring entities to include franchise tax partially based on income as an income based tax and to account for an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. The guidance in ASU 2019-12 is required for annual reporting periods beginning after December 15, 2020. Adoption of ASU 2019-12 had no material effect on our consolidated financial statements and disclosures.

#### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Certain statements within "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements that involve risks and uncertainties. Words such as may, will, should, would, anticipates, expects, intends, plans, believes, seeks, estimates and similar expressions identify such forward-looking statements. The forward-looking statements contained herein are based on current expectations and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Factors that might cause such a difference include, among other things, those set forth under "Liquidity and Capital Resources" below and under "Risk Factors" in Part I, Item 1A to our annual report on Form 10-K for the year ended December 31, 2020, which discussion is incorporated herein by reference. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. We assume no obligation to update these forward-looking statements to reflect actual results or changes in factors or assumptions affecting forward-looking statements, except as may be required by law.

#### Overview

We are primarily a producer of ion implantation equipment used in the fabrication of semiconductor chips in the United States, Europe and Asia. In addition, we provide extensive worldwide aftermarket service and support, including spare parts, equipment upgrades and maintenance services to the semiconductor industry. Our product development and manufacturing activities currently occur primarily in the United States although we are adding additional manufacturing capacity in South Korea that should come online by year end 2021. Our equipment and service products are highly technical and are sold through a direct sales force in the United States, Europe and Asia. Consolidation and partnering within the semiconductor manufacturing industry has resulted in a small number of customers representing a substantial portion of our business. Our ten largest customers accounted for 71.1% of total revenue for the six months ended June 30, 2021.

In the first half of 2021, we delivered strong financial performance driven by strong semiconductor industry fundamentals and an increasing demand for our Purion products, especially in the high growth power device market. The rapid acceleration of the electrification of the automotive industry is creating substantial demand for power devices and image sensors, which is driving sustainable growth for the Purion product extensions specifically developed for these markets.

Despite the many difficult logistical challenges brought on by trade tensions between the United States and China and COVID-19, we are continuing to work closely with our customers across market segments to provide them with the best ion implant solutions for their specific manufacturing challenges.

In December 2020, the United States Commerce Department placed one of our major Chinese customers, Semiconductor Manufacturing International Corporation ("SMIC"), on the U.S. export controls Entity List. As a result of the Entity List classification, we are required to obtain export controls licenses for all U.S. shipments to this customer. Although we have begun receiving these licenses, this situation did delay some shipments to this customer in the first half of 2021.

#### **Critical Accounting Estimates**

Management's discussion and analysis of our financial condition and results of operations included herein and in our Annual Report on Form 10-K for the year ended December 31, 2020 are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and assumptions. Management's estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Management has not identified any need to make any material change in, and has not changed, any of our critical accounting estimates and judgments as described in Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2020.

#### **Results of Operations**

The following table sets forth our results of operations as a percentage of total revenue:

	Three month June 3		Six months ended June 30,		
	2021	2020	2021	2020	
Revenue:					
Product	95.2 %	95.3 %	95.3 %	94.8 %	
Services	4.8	4.7	4.7	5.2	
Total revenue	100.0	100.0	100.0	100.0	
Cost of revenue:					
Product	52.1	53.3	52.5	54.8	
Services	4.5	4.5	4.5	4.9	
Total cost of revenue	56.6	57.8	57.0	59.7	
Gross profit	43.4	42.2	43.0	40.3	
Operating expenses:					
Research and development	11.3	13.0	11.5	12.7	
Sales and marketing	8.3	7.7	8.1	7.3	
General and administrative	7.6	8.2	7.6	7.9	
Total operating expenses	27.2	28.9	27.2	27.9	
Income from operations	16.2	13.3	15.8	12.4	
Other (expense) income:					
Interest income	_	0.1	_	0.2	
Interest expense	(0.9)	(1.1)	(8.0)	(1.1)	
Other, net	_	0.3	(0.4)	(0.1)	
Total other expense	(0.9)	(0.7)	(1.2)	(1.0)	
Income before income taxes	15.3	12.6	14.6	11.4	
Income tax provision	2.6	1.8	2.0	1.4	
Net income	12.7 %	10.8 %	12.6 %	10.0 %	

#### Revenue

The following table sets forth our product and services revenue:

	Three mont		Period-to- Chan			hs ended e 30,		Period-to-Po Change	
	2021	2020	\$	% (dollars i	2021 n thousands)	2020	_	\$	%
Revenue:									
Product	\$ 140,156	\$ 117,194	\$ 22,962	19.6 %	\$ 266,765	\$ 229,327	\$	37,438	16.3 %
Percentage of revenue	95.2 %	95.3 %	ó		95.3 %	94.8 %	6		
Services	7,118	5,771	1,347	23.3 %	13,285	12,629		656	5.2 %
Percentage of revenue	4.8 %	4.7 %	ó		4.7 %	5.2 %	6		
Total revenue	\$ 147,274	\$ 122,965	\$ 24,309	19.8 %	\$ 280,050	\$ 241,956	\$	38,094	<i>15.7</i> %

#### Three months ended June 30, 2021 Compared with Three months ended June 30, 2020

#### Product

Product revenue, which includes systems sales, sales of spare parts, product upgrades and used systems was \$140.2 million, or 95.2% of revenue during the three months ended June 30, 2021, compared with \$117.2 million, or 95.3% of revenue for the three months ended June 30, 2020. The \$23.0 million increase in product revenue for the three-month period ending June 30, 2021, in comparison to the same period in 2020, was primarily driven by an increase in the number of systems sold.

A portion of our revenue from systems sales is deferred until installation and other services related to future performance obligations are performed. The total amount of deferred revenue at June 30, 2021 and December 31, 2020 was \$35.5 million and \$23.1 million, respectively. The increase in deferred revenue was primarily due to customer prepayments for systems.

#### Services

Services revenue, which includes the labor component of maintenance and service contracts and fees for service hours provided by on-site service personnel, was \$7.1 million, or 4.8% of revenue for the three months ended June 30, 2021, compared with \$5.8 million, or 4.7% of revenue for the three months ended June 30, 2020. Although services revenue typically increases with the expansion of the installed base of systems, it can fluctuate from period to period based on capacity utilization at customers' manufacturing facilities, which affects the need for equipment service.

#### Six months ended June 30, 2021 Compared with Six months ended June 30, 2020

#### Product

Product revenue was \$266.8 million, or 95.3% of revenue during the six months ended June 30, 2021, compared with \$229.3 million, or 94.8% of revenue for the six months ended June 30, 2020. The \$37.4 million increase in product revenue for the six-month period ending June 30, 2021, in comparison to the same period in 2020, was primarily driven by an increase in the number of systems sold and to a lesser extent revenue increases in spare parts, product upgrades and used systems.

#### Services

Services revenue was \$13.3 million, or 4.7% of revenue for the six months ended June 30, 2021, compared with \$12.6 million, or 5.2% of revenue for the six months ended June 30, 2020.

#### **Revenue Categories used by Management**

In addition to the line item revenue categories discussed above, management also regularly disaggregates revenue in the following categories, which it finds relevant and useful:

- Ion implant revenue separate from revenue from legacy non-ion implant product lines, given that ion implantation systems are the primary driver of our growth and strategic objectives;
- Systems and Aftermarket revenues, in which "Aftermarket" is:
  - A. The portion of Product revenue relating to spare parts, product upgrades and used equipment, combined with
  - B. Services revenue, which is the labor component of Aftermarket revenues

(Aftermarket purchases reflect current fab utilization as opposed to Systems purchases which reflect capital investment decisions by our customers, which have differing economic drivers);

- Revenue by geographic regions, since economic factors impacting customer purchasing decisions may vary by geographic region; and
- Revenue by our customer market segments, since they can be subject to different economic drivers at
  different periods of time, impacting a customer's likelihood of purchasing capital equipment during any
  particular period. Currently, management references three customer market segments: memory, mature
  technology processes and leading edge foundry and logic.

The ion implant and Aftermarket revenue categories for recent periods are discussed below.

#### Three months ended June 30, 2021 Compared with Three months ended June 30, 2020

#### Ion Implant

Included in total revenue of \$147.3 million during the three months ended June 30, 2021 is revenue from sales of ion implant products and services of \$142.9 million, or 97.0% of total revenue, compared with \$118.7 million, or 96.6%, of total revenue for the three months ended June 30, 2020. The remaining \$4.4 million of revenue for the three months ended June 30, 2021 was non-ion implant parts and services.

#### Aftermarket

Included in total revenue of \$147.3 million during the three months ended June 30, 2021 is revenue from our Aftermarket business of \$47.1 million, compared to \$46.2 million for the three months ended June 30, 2020. The remaining \$100.2 million of revenue for the three months ended June 30, 2021 was from system sales. Aftermarket revenue fluctuates from period to period based on capacity utilization at customers' manufacturing facilities, which affects the sale of spare parts and demand for equipment service. Aftermarket revenue can also fluctuate from period to period based on the demand for system upgrades or used equipment.

#### Six months ended June 30, 2021 Compared with Six months ended June 30, 2020

#### Ion Implant

Included in total revenue of \$280.1 million during the six months ended June 30, 2021 is revenue from sales of ion implant products and services of \$271.6 million, or 97.0% of total revenue, compared with \$233.8 million, or 96.6%, of total revenue for the six months ended June 30, 2020. The remaining \$8.5 million of revenue for the six months ended June 30, 2021 was non-ion implant parts and services.

#### Aftermarket

Included in total revenue of \$280.1 million during the six months ended June 30, 2021 is revenue from our Aftermarket business of \$98.9 million, compared to \$82.8 million for the six months ended June 30, 2020. The remaining \$181.2 million of revenue for the six months ended June 30, 2021 was from system sales.

#### **Gross Profit / Gross Margin**

The following table sets forth our gross profit / gross margin:

	Three months June 3				Six months June 3		d Period-to-Period Change	
	2021	2020	\$	(dollars in t	2021 thousands)	2020	\$	%
Gross Profit:				•	ĺ			
Product	\$ 63,468 \$	51,675	\$ 11,793	22.8 %	\$ 119,743	\$ 96,636	\$ 23,107	23.9 %
Product gross margin	45.3 %	44.1 %			44.9 %	42.1 %		
Services	546	224	322	(143.8)%	706	812	(106)	(13.1)%
Services gross margin	7.7 %	3.9 %			5.3 %	6.4 %		
Total gross profit	\$ 64,014 \$	51,899	\$ 12,115	23.3 %	\$ 120,449	\$ 97,448	\$ 23,001	23.6 %
Gross margin	43.4 %	42.2 %			43.0 %	40.3 %		

Three months ended June 30, 2021 Compared with Three months ended June 30, 2020

#### Product

Gross margin from product revenue was 45.3% for the three months ended June 30, 2021, compared to 44.1% for the three months ended June 30, 2020. The increase resulted from improved gross margins on parts and upgrades and Purion systems.

#### Services

Gross margin from services revenue was 7.7% for the three months ended June 30, 2021, compared to 3.9% for the three months ended June 30, 2020. The increase in gross margin is attributable to changes in the mix of service contracts.

#### Six months ended June 30, 2021 Compared with Six months ended June 30, 2020

#### Product

Gross margin from product revenue was 44.9% for the six months ended June 30, 2021, compared to 42.1% for the six months ended June 30, 2020. The increase in gross margin resulted from an increased mix of higher margin parts and upgrades and improved margins on Purion systems.

#### Services

Gross margin from services revenue was 5.3% for the six months ended June 30, 2021, compared to 6.4% for the six months ended June 30, 2020. The decrease in gross margin is attributable to changes in the mix of service contracts.

#### **Operating Expenses**

The following table sets forth our operating expenses:

	Three mont		Period-to Cha		Six months June 3			o-Period inge
	2021	2020	\$	%	2021	2020	\$	%
	<u> </u>			(dollars in	thousands)			
Research and development	\$ 16,623	\$ 16,040 \$	583	3.6 % 5	32,308	30,646	\$ 1,662	5.4 %
Percentage of revenue	11.3 %	13.0 %			11.5 %	12.7 %		
Sales and marketing	12,177	9,437	2,740	29.0 %	22,564	17,641	4,923	27.9 %
Percentage of revenue	8.3 %	7.7 %			8.1 %	7.3 %		
General and administrative	11,217	10,041	1,176	11.7 %	21,230	19,077	2,153	11.3 %
Percentage of revenue	7.6 %	8.2 %	•		7.6 %	7.9 %	·	
Total operating expenses	\$ 40,017	\$ 35,518 \$	4,499	12.7 %	5 76,102	67,364	\$ 8,738	13.0 %
Percentage of revenue	27.2 %	28.9 %	,	-	27.2 %	27.9 %		

Our operating expenses consist primarily of personnel costs, including salaries, commissions, incentive based compensation, stock-based compensation and related benefits and taxes; project material costs related to the design and development of new products and enhancement of existing products; and professional fees, travel and depreciation expenses.

Personnel costs are our largest expense, representing \$25.4 million or 63.5% of our total operating expenses for the three months ended June 30, 2021, compared to \$22.8 million or 64.3% of our total operating expenses for the three months ended June 30, 2020. Personnel costs were \$47.5 million or 62.4% of our total operating expenses for the six months ended June 30, 2021, compared to \$42.8 million or 63.5% of our total operating expenses for the six months ended June 30, 2020. The higher personnel costs for the three and six months ended June 30, 2021 is primarily due to an increase in personnel expenses to support growth.

#### **Research and Development**

		Three months ended June 30,		Period-to-Period Change		Six months ended June 30,		Period-to Char	
	2021	2020	\$	%	2021	2020		\$	%
				(dolla	rs in thousand	ls)			
Research and development	\$ 16,623	\$ 16,040	\$ 583	3.6 %	\$ 32,308	\$ 30,646	\$	1,662	5.4 %
Percentage of revenue	11.3 %	% 13.0 9	%		11.5 %	6 12.7 %	6		

Our ability to remain competitive depends largely on continuously developing innovative technology, with new and enhanced features and systems and introducing them at competitive prices on a timely basis. Accordingly, based on our strategic plan, we establish annual R&D budgets to fund programs that we expect will solve customers' high value, high impact, ion implantation challenges.

#### Three months ended June 30, 2021 Compared with Three months ended June 30, 2020

Research and development expense was \$16.6 million during the three months ended June 30, 2021, an increase of \$0.6 million, or 3.6%, compared with \$16.0 million during the three months ended June 30, 2020. The increase is primarily due to higher personnel expenses and incentive based pay expense.

#### Six months ended June 30, 2021 Compared with Six months ended June 30, 2020

Research and development expense was \$32.3 million during the six months ended June 30, 2021, an increase of \$1.7 million, or 5.4%, compared with \$30.6 million during the six months ended June 30, 2020. The increase is primarily due to higher personnel expenses, supplies and materials costs for ongoing projects and increased depreciation associated with capital additions.

#### **Sales and Marketing**

		Three months ended June 30,		Period-to-Period Change		Six months ended June 30,		-Period 1ge
	2021	2020	\$	%	2021	2020	\$	%
	<u></u>			(dollars i	n thousands			
Sales and marketing	\$ 12,177	\$ 9,437	\$ 2,740	29.0 %	\$ 22,564	\$ 17,641	\$ 4,923	<i>27.9</i> %
Percentage of revenue	8.3 %	% 7.7 9	6		8.1 9	% 7.3 9	6	

Our sales and marketing expenses result primarily from the sale of our equipment and services through our direct sales force.

#### Three months ended June 30, 2021 Compared with Three months ended June 30, 2020

Sales and marketing expense was \$12.2 million during the three months ended June 30, 2021, an increase of \$2.7 million, or 29.0%, compared with \$9.4 million during the three months ended June 30, 2020. The increase is primarily due to increases in freight expense and project material costs as well as higher personnel related expenses.

#### Six months ended June 30, 2021 Compared with Six months ended June 30, 2020

Sales and marketing expense was \$22.6 million during the six months ended June 30, 2021, an increase of \$4.9 million, or 27.9%, compared with \$17.6 million during the six months ended June 30, 2020. The increase is primarily due to increases in freight expense and project material costs as well as higher personnel related expenses.

#### **General and Administrative**

		Three months ended June 30,		o-Period inge	Six months ended June 30,		Period-to Chai	
	2021	2020	\$	%	2021	2020	\$	%
				(dollars in	thousands)		<u> </u>	
General and administrative	\$ 11,217	\$ 10,041	\$ 1,176	11.7 %	\$ 21,230	\$ 19,077	\$ 2,153	11.3 %
Percentage of revenue	7.6 %	6 8.2 9	%		7.6 9	% 7.9 °	%	

Our general and administrative expenses result primarily from the costs associated with our executive, finance, information technology, legal and human resource functions.

#### Three months ended June 30, 2021 Compared with Three months ended June 30, 2020

General and administrative expense was \$11.2 million during the three months ended June 30, 2021, an increase of \$1.2 million, or 11.7%, compared with \$10.0 million during the three months ended June 30, 2020. The increase is primarily due to an increase in personnel expenses and incentive based pay expense.

#### Six months ended June 30, 2021 Compared with Six months ended June 30, 2020

General and administrative expense was \$21.2 million during the six months ended June 30, 2021, an increase of \$2.2 million, or 11.3%, compared with \$19.1 million during the six months ended June 30, 2020. The increase is primarily due to an increase in personnel expenses and incentive based pay expense.

#### Other (Expense) Income

		Three months ended June 30,		Period-to-period change		Six months ended June 30,		period ge
	2021	2020	\$	%	2021	2020	\$	%
				(dollars in	thousands)			
Other expense	\$ (1,249) \$	(808)	441	54.6 %	\$ (3,398)	\$ (2,249)	\$ 1,149	51.1 %
Percentage of revenue	(0.9)%	(0.7)%			(1.2)%	(1.0)%	á	

Other (expense) income consists primarily of interest expense relating to the finance lease obligation we incurred in connection with the 2015 sale of our headquarters facility and other financing obligations, foreign exchange gains and losses attributable to fluctuations of the U.S. dollar against local currencies of certain of the countries in which we operate as well as interest earned on our invested cash balances.

Other expense was \$1.2 million for the three months ended June 30, 2021, compared with \$0.8 million for the three months ended June 30, 2020. The increase in other expense was primarily due to an increase in foreign currency exchange losses. Other expense was \$3.4 million for the six months ended June 30, 2021, compared with \$2.2 million for the six months ended June 30, 2020. The increase in other expense was primarily due to an increase in foreign currency exchange losses of \$0.6 million as well as a reduction of \$0.5 million in interest income when compared to the six-month period ended June 30, 2020.

During the six-month periods ended June 30, 2021 and 2020, we had no significant off-balance-sheet risk such as exchange contracts, option contracts or other hedging arrangements.

#### **Income Tax Provision**

		nths ended e 30,	Period-to		Six mont		Period-to	•
	2021	2020	\$	%	2021	2020	\$	%
				(dollars i	n thousands)			
Income tax provision	\$ 3,842	\$ 2,271	\$ 1,571	(69.2)%	\$ 5,563	\$ 3,312	\$ 2,251	68.0 %
Percentage of revenue	2.6 %	6 1.8 9	%		2.0 %	1.4	%	

Income tax expense was \$3.8 million for the three months ended June 30, 2021, compared to \$2.3 million for the three months ended June 30, 2020. The \$1.5 million increase was primarily due to a \$7.2 million increase in pretax income. Income tax expense was \$5.6 million during the six months ended June 30, 2021, compared to \$3.3 million for the six months ended June 30, 2020. The \$2.3 million increase was primarily due to a \$13.1 million increase in pretax income. The effective tax rate for the three and six months ended June 30, 2021 and 2020, respectively, was less than the U.S. statutory rate of 21% due to favorable discrete items related to equity compensation in those periods as well as Federal research and development tax credits that reduce the annual tax rate.

We had \$51.4 million and \$57.9 million of net deferred tax assets worldwide relating to net operating loss carryforwards, tax credit carryforwards and other temporary differences, as of June 30, 2021 and December 31, 2020, respectively. These deferred tax assets are available to reduce income taxes in future years. We have a \$9.1 million valuation allowance in the U.S. against certain tax credits and state net operating losses due to the uncertainty of their realization based on long-term Company forecasts and the expiration dates on these tax assets. If future operating results of the Company within the U.S. or these foreign jurisdictions are significantly less than our expectations, it is reasonably possible that we would be required to record an additional valuation allowance on our deferred tax assets in the future.

#### **Liquidity and Capital Resources**

We had \$219.7 million in unrestricted cash and cash equivalents at June 30, 2021, in addition to \$0.8 million in restricted cash. Management believes that maintaining a strong cash balance is necessary to provide funding for potential ramps in our business which can require significant cash investment to meet sudden demand. Additionally, we are using cash in our 2021 stock repurchase program and are considering both organic and inorganic opportunities to drive future growth, for which cash resources will be necessary.

Our liquidity is affected by many factors. Some of these relate specifically to the operations of our business, for example, the rate of sale of our products, and others relate to the uncertainties of global economic conditions, including the availability of credit and the condition of the overall semiconductor equipment industry. Our established cost structure, other than cost of goods sold, does not vary significantly with changes in volume. We experience fluctuations in operating results and cash flows depending on these factors. Stock repurchases, as discussed below, also reduce our cash balances.

During the six months ended June 30, 2021, we generated \$45.9 million of cash related to operating activities. During the six months ended June 30, 2020, we generated \$56.6 million of cash related to operating activities.

Investing activities for the six months ended June 30, 2021 and 2020 resulted in cash outflows of \$2.4 million and \$3.0 million, respectively, used for capital expenditures.

Financing activities for the six months ended June 30, 2021 resulted in a cash usage of \$28.3 million. During the first six months of 2021, \$25.0 million in cash was used to repurchase our common stock and \$6.5 million was used for payments to government tax authorities for income tax withholding on employee compensation arising from the vesting of RSUs, where shares are withheld by the Company, as well as \$0.4 million relating to the reduction of the liability under the finance lease of our corporate headquarters. These amounts were partially offset by \$3.6 million of proceeds from the exercise of stock options and purchase of shares under our 2020 ESPP during the first six months of 2021. In comparison, financing activities for the six months ended June 30, 2020 resulted in cash usage of \$3.7 million, \$7.5 million of which related to the repurchase of our common stock and \$3.9 million related to payments made to government tax authorities for income tax withholding on employee compensation arising from the vesting of RSUs, as well as \$0.1 million relating to the reduction of our financing lease liability. These amounts were partially offset by \$7.8 million of proceeds related to the exercise of stock options and purchase of shares under our prior employee stock purchase plan during the first six months of 2020.

Under the rules of the U.S. Securities and Exchange Commission (the "SEC"), we qualify as a "well-known seasoned issuer," which allows us to file shelf registration statements to register an unspecified amount of securities that are effective upon filing. On May 29, 2020, we filed such a shelf registration statement with the SEC for the issuance of an unspecified amount of common stock, preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in units, from time to time at prices and on terms to be determined at the time of any such offering. This registration statement was effective upon filing and will remain in effect for up to three years from filing, prior to which time we may file another shelf registration statement to maintain the availability of this financing option.

On July 31, 2020, we entered into a Senior Secured Credit Facilities Credit Agreement (the "Credit Agreement") with Silicon Valley Bank. The Credit Agreement provides for a revolving credit facility in an aggregate principal amount not to exceed \$40.0 million. Our obligations under the Credit Agreement are secured by a security interest, senior to any current and future debts and to any security interest, in all of our rights, title, and interest in, to and under substantially all of our assets, subject to limited exceptions, including permitted liens. The revolving credit facility terminates on July 31, 2023. As of June 30, 2021, we were in compliance with all covenant requirements of the Credit Agreement. As of such date, no borrowings had been made under the Credit Agreement, although a letter of credit for \$5.9 million reduces the funds available for borrowing under the credit line. We have no immediate plans to borrow under the Credit Agreement, but we will use the facility for letters of credit, for ongoing working capital needs and to fund general corporate purposes, as desired. We entered into a First Amendment to the Credit Agreement with Silicon Valley Bank in March 2021 to (i) align the covenants with our 2021 stock repurchase program, and (ii) establish terms to transition from a Eurodollar based interest rate option to an interest rate benchmark using a secured overnight financing rate (known as "SOFR") published by the Federal Reserve Bank of New York.

We believe that based on our current market, revenue, expense and cash flow forecasts, our existing cash, cash equivalents and equity and debt financing capacity will be sufficient to satisfy our anticipated cash requirements for the short and long-term.

#### **Commitments and Contingencies**

Significant commitments and contingencies at June 30, 2021 are consistent with those discussed in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," and Note 16 to the consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

#### Item 3. Quantitative and Qualitative Disclosures about Market Risk.

As of June 30, 2021, there have been no material changes to the quantitative information about market risk disclosed in Item 7A to our Annual Report on Form 10-K for the year ended December 31, 2020.

#### Item 4. Controls and Procedures.

#### **Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report (the "Evaluation Date"). Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the Evaluation Date, these disclosure controls and procedures are effective.

#### **Changes in Internal Control over Financial Reporting**

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during the three months ended June 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

#### PART II—OTHER INFORMATION

#### Item 1. Legal Proceedings.

We are, from time to time, a party to litigation that arises in the normal course of our business operations. We are not presently a party to any litigation that we believe might have a material adverse effect on our business operations.

#### Item 1A. Risk Factors.

As of June 30, 2021, there have been no material changes to the risk factors described in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2020.

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In December 2020, our Board of Directors authorized a share repurchase program covering 2021 for up to \$100 million of the Company's common stock.

The following table summarizes the stock repurchase activity, based upon settlement date, for the three months ended June 30, 2021 as well as the approximate dollar value of shares that may yet be purchased pursuant to our stock repurchase program:

			Total Number of Shares Purchased as	Approximate Dollar Value of Shares that May Yet Be
	Total Number of Shares Purchased	Average Price Paid per Share	Part of Publicly Announced Program	Purchased Under the Program
' <u> </u>		(in thousands e	xcept per share amounts)	
April 1, 2021 through April 30, 2021	117	\$43.35	117	\$ 83,286
May 1, 2021 through May 31, 2021	100	\$39.74	100	79,312
June 1, 2021 through June 30, 2021	106	\$40.74	106	\$ 75,006
Total	323		323	

#### Item 3. Defaults Upon Senior Securities.

None.

#### Item 4. Mine Safety Disclosures.

Not Applicable.

#### Item 5. Other Information.

None.

#### Item 6. Exhibits.

The following exhibits are filed herewith:

Exhibit No	Description
3.1	Restated Certificate of Incorporation of the Company filed November 2, 2017. Incorporated by reference to Exhibit 3.1 of the Company's Form 10-Q filed with the Commission on November 3, 2017.
3.2	Bylaws of the Company, as amended as of May 13, 2014. Incorporated by reference to Exhibit 3.2 of the Company's Form 8-K filed with the Commission on May 19, 2014.
31.1	Certification of the Principal Executive Officer under Exchange Act Rule 13a-14(a)/15d-14(a) (Section 302 of the Sarbanes-Oxley Act), dated August 6, 2021. Filed herewith.
31.2	Certification of the Principal Financial Officer under Exchange Act Rule 13a-14(a)/15d-14(a) (Section 302 of the Sarbanes-Oxley Act), dated August 6, 2021. Filed herewith.
32.1	Certification of the Principal Executive Officer pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code (Section 906 of the Sarbanes-Oxley Act), dated August 6, 2021. Filed herewith.
32.2	Certification of the Principal Financial Officer pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code (Section 906 of the Sarbanes-Oxley Act), dated August 6, 2021. Filed herewith.
101	The following materials from the Company's Form 10-Q for the quarter ended June 30, 2021, formatted in inline eXtensible Business Reporting Language (iXBRL): (i) Consolidated Statements of Operations, (ii) Consolidated Statements of Comprehensive Income, (iii) Consolidated Balance Sheets, (iv) Consolidated Statements of Cash Flows and (v) Notes to Consolidated Financial Statements (Unaudited). Filed herewith.
104	Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibit 101).
	30

DATED: August 6, 2021

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AXCELIS TECHNOLOGIES, INC.

By: /s/ KEVIN J. BREWER

Kevin J. Brewer

Executive Vice President and Chief Financial Officer Duly Authorized Officer and Principal Financial Officer

#### CERTIFICATION

### of the Principal Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) (implementing Section 302 of the Sarbanes-Oxley Act)

#### I, Mary G. Puma, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of Axcelis Technologies, Inc.;
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
  material fact necessary to make the statements made, in light of the circumstances under which such statements
  were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 6, 2021 /s/ MARY G. PUMA

Mary G. Puma,
President and Chief Executive Officer

#### **CERTIFICATION**

### of the Principal Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) (implementing Section 302 of the Sarbanes-Oxley Act)

#### I, Kevin J. Brewer, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of Axcelis Technologies, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 6, 2021 /s/ KEVIN J. BREWER

Kevin J. Brewer, Executive Vice President and Chief Financial Officer

### AXCELIS TECHNOLOGIES, INC. Certification of the Principal Executive Officer Pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code

The undersigned Chief Executive Officer of Axcelis Technologies, Inc., a Delaware corporation, hereby certifies, for the purposes of Section 1350 of Chapter 63 of title 18 of the United States Code (as implemented by Section 906 of the Sarbanes-Oxley Act of 2002) as follows:

This Form 10-Q quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and the information contained herein fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Certification as of August 6, 2021.

/s/ MARY G. PUMA

Mary G. Puma President and Chief Executive Officer of Axcelis Technologies, Inc.

#### AXCELIS TECHNOLOGIES, INC. Certification of the Principal Financial Officer Pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code

The undersigned Chief Financial Officer of Axcelis Technologies, Inc., a Delaware corporation, hereby certifies, for the purposes of Section 1350 of Chapter 63 of title 18 of the United States Code (as implemented by Section 906 of the Sarbanes-Oxley Act of 2002) as follows:

This Form 10-Q quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and the information contained herein fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has executed this Certification as of August 6, 2021.

/s/ KEVIN J. BREWER

Kevin J. Brewer Executive Vice President and Chief Financial Officer of Axcelis Technologies, Inc.